{'fraction_non_alphanumeric': 0.02127659574468085, 'fraction_numerical': 0.006648936170212766, 'mean_word_length': 5.121951219512195, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Ticlopidine-induced aplastic anemia. A case report and review of the literature].

Ticlopidine, an inhibitor of platelet aggregation, is widely used for peripheral arterial disease. The use of this drug has been associated with neutropenie and other adverse hematologic effects. Aplastic anemie is a rate complication that carries high mortality. We describe the case of a 91 years old woman with ticlopedine-induced aplastic anemia. The patient was treated with filgrastim brood spectrum antibiotics and other general supportive care measures. Despite initial improvement the old woman died 7 weeks after admission for septic shock. A review of medical literature revealed 24 similar cases. Filgrastim has been used previous by with variable success.